Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. [electronic resource]
Producer: 20110106Description: 95-104 p. digitalISSN:- 1618-7601
- Aged
- Antibodies, Monoclonal, Murine-Derived -- economics
- Antirheumatic Agents -- economics
- Arthritis, Rheumatoid -- drug therapy
- Cost-Benefit Analysis
- Etanercept
- Female
- Germany
- Humans
- Immunoglobulin G -- economics
- Immunosuppressive Agents -- economics
- Male
- Markov Chains
- Middle Aged
- Models, Econometric
- Probability
- Quality-Adjusted Life Years
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Rituximab
- Surveys and Questionnaires
- Treatment Failure
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.